Latest Headlines

  1. BPSA Releases Guide To Production Of Cell And Gene Therapies
    2/21/2019

    The Bio-Process Systems Alliance, the primary international industry association for single-use bio-processing, is pleased to announce the release of its latest white paper, The Role of Single-Use Polymeric Solutions in Enabling Cell and Gene Therapy Production, compiled by a select committee of experts in the fields of single-use technology (SUT) and cell and gene therapies.

  2. Allogene Therapeutics Enters Lease To Build Manufacturing Facility To Develop And Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
    2/20/2019

    Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a lease agreement to develop a 118,000 square foot cell therapy manufacturing facility in Newark, California.

  3. AveXis To Invest $60 Million Into New Gene Therapy Drug Manufacturing Facility In North Carolina
    2/19/2019

    AveXis, Inc., a leading gene therapy company developing treatments for rare and life-threatening neurological diseases, will invest $60M to expand its manufacturing center in Durham County, North Carolina. The company plans to hire 200 associates.

  4. IPS Showcases INNOPHEX And Pharma 4.0 At Their Annual Technologies Tours At INTERPHEX
    2/19/2019

    IPS-Integrated Project Services, LLC (IPS), a leading provider of Engineering, Procurement, Construction Management and Validation (EPCMV) services, announces the ninth annual IPS Technologies Tours at INTERPHEX with Tours focused on the hottest trends in the industry, including Pharma 4.0 concepts, cell processing, and gene therapy.

     

  5. G-CON Manufacturing And GE Healthcare Announce Collaboration To Advance Early-Stage Cell Therapy And Viral Vector Manufacturing
    1/22/2019

    G-CON Manufacturing, the leader in prefabricated flexible cleanroom solutions (“PODs”) and GE Healthcare plan to collaborate to improve cell therapy and viral vector manufacturing by providing drug developers with a combined, flexible, and readily deployable manufacturing platform suitable for early-stage clinical or commercial production.

  6. Orchard Therapeutics To Invest $150M Into New Gene Therapy Manufacturing Facility In California
    12/13/2018

    Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that it has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California.

  7. Cell Processing, Gene Therapy And Pharma 4.0 To Be Featured At Interphex 2019
    11/28/2018

    International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology and knowledge from development through commercialization, announces INNOPHEX will debut at INTERPHEX 2019.

  8. Cobra Biologics, Pall Corporation And The Cell And Gene Therapy Catapult Win £1.5M Innovate UK Grant To Investigate Continuous Manufacturing For Gene Therapies
    11/27/2018

    Cobra Biologics, an international contract development and manufacturing organization (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.

  9. Reducing The Risk Of Bio-contamination In Gene, Cell And CAR-T Therapy
    11/7/2018

    Bioquell’s Dr Rolf Hansen examines how the latest isolator systems create aseptic working conditions for reducing risk and keeping gene, cell and CAR-T therapies efficient, compliant and accurate, whilst also supporting biologics manufacturing expansion and enabling more patients to be treated at the same time.

  10. How To Implement Cleanroom Upgrades While Operating Your Facility
    10/29/2018

    It goes without saying that upgrades during a manufacturing shutdown pose less risk as there are no products being produced, but there are instances when it is critical to expand capacity or modify functionality while maintaining some processing.